Skip to content
AnalystLens

Somnigroup International Annual Report, Year Ended Dec 31, 2004

Filing Date
Filed March 8, 2005
Period End
December 31, 2004
Security
SGI
In the record · 2016–202610-K1110-Q328-K220

SGI filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 220 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jun ’17Jun ’17
  2. Material agreement8-K · Oct ’19Oct ’19
  3. Leadership change8-K · Dec ’21Dec ’21
  4. Leadership change8-K · Sep ’25Sep ’25

Summary

Summary of the 10-K filed March 8, 2005. Cited figures are marked; the original filing is the authoritative source.

Tempur-Pedic International Inc. (now Somnigroup International) reported net sales of $684.9 milliona for 2004, up from $479.1 million in 2003, an increase of $205.8 million, or 43%.

Gross profit rose to $361.0 millionb (53% of net sales), operating income to $151.0 million (22% of net sales), and net income to $75.0 million (11% of net sales). Diluted earnings per share were $0.73, compared with $0.39 in 2003. International sales accounted for approximately 37% of 2004 net sales.

Growth was led by the Retail channel, which rose $176.1 millionc, or 56%, to $489.5 million, while mattresses represented 63% of sales and pillows 20%. The company's balance sheet strengthened over the year. Long-term debt fell to $289.7 million from $376.5 million, and stockholders' equity rose to $213.6 million from $122.7 million.

Operating cash flow was $77.0 milliond and capital expenditures were $38.4 million. Management expects 2005 capital expenditures of approximately $94.0 million, including about $70.5 million for the Albuquerque, New Mexico manufacturing facility, which is expected to be completed by the second quarter of 2006 at an estimated cost of $90.0 million. The filing also notes risks including leverage, competition from larger rivals, dependence on two polyol suppliers, product liability exposure, and a 120-day return policy that generated approximately $30.7 million in U.S. returns in 2004.

The company, which completed its initial public offering in December 2003 and trades on the NYSE under the symbol TPX, does not pay dividends and intends to retain earnings to fund growth. Its principal stockholders, TA Associates and Friedman Fleischer & Lowe, together owned approximately 49% of fully diluted common stock at December 31, 2004.

Key Highlights

  1. Net sales of $684.9 million in 2004, up 43% from $479.1 million in 2003
  2. Gross profit of $361.0 million, 53% of net sales; net income of $75.0 million, 11% of net sales
  3. Diluted EPS of $0.73 in 2004 versus $0.39 in 2003
  4. Long-term debt reduced to $289.7 million from $376.5 million; stockholders' equity increased to $213.6 million
  5. Retail channel sales rose to $489.5 million, up $176.1 million or 56%, making it the largest channel at 71% of net sales
  6. International sales were approximately 37% of net sales; operating cash flow was $77.0 million
  7. Albuquerque, New Mexico manufacturing plant under construction at an estimated cost of $90.0 million, expected to be completed by the second quarter of 2006

Frequently Asked Questions

  1. What drove the revenue growth in 2004?

    The filing attributes the 43% increase in net sales primarily to the execution of the company's strategy of building global brand awareness and penetrating existing channels. Growth was realized across all channels, with Retail up $176.1 million, or 56%, Direct up 15%, Healthcare up 8%, and Third party up 38%. Foreign currency fluctuations contributed approximately $22.5 million of the increase.

  2. How much debt does the company carry and how is it changing?

    Long-term debt was $289.7 million at December 31, 2004, down from $376.5 million at December 31, 2003. Total senior debt was $192.2 million. The company redeemed $52.5 million of its 10 1/4% Senior Subordinated Notes in January 2004 using IPO proceeds. Management states that operating margins should enable continued de-leveraging, though it also notes that high leverage limits flexibility and increases default risk.

  3. What are the main risks identified in the filing?

    Key risks include intense competition from larger manufacturers with greater resources, the potential for price reductions on premium products, product liability exposure, return rates on the 120-day money-back guarantee, reliance on two polyol suppliers for raw materials, dependence on a few significant customers (the top five accounted for 13% of 2004 net sales), currency fluctuations, and the company's high leverage. Two of the company's own manufacturing plants produce all of its products, so any production disruption could affect sales.

  4. What are the company's capital spending plans?

    Capital expenditures were $38.4 million in 2004. The company expects 2005 capital expenditures of approximately $94.0 million, including about $70.5 million for the Albuquerque, New Mexico facility and about $10.0 million for enhancements to existing assets. The Albuquerque plant, a 750,000 square foot facility, is estimated to cost $90.0 million in total and is expected to be completed by the second quarter of 2006.

  5. Does the company pay dividends, and who controls the company?

    The company does not pay dividends on its common stock and intends to retain earnings to fund growth, although it made a $160.0 million return-of-capital distribution in connection with its August 2003 recapitalization. At December 31, 2004, TA Associates and Friedman Fleischer & Lowe owned approximately 49% of fully diluted common stock, and executive officers, directors and principal stockholders together owned approximately 57% on a fully diluted basis, which the filing says allows them to control substantially all matters requiring stockholder approval.